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A new chimeric gene ApE1 encoding the receptor-binding domain of the human alpha-fetoprotein fused to a sequence of 22
glutamic acid residues was constructed. A new bacterial producer strain E. coli SHExT7 ApE1 was selected for ApE1 production
in a soluble state. A simpliﬁed method was developed to purify ApE1 from bacterial biomass. It was shown that the new vector
protein selectively interacts with AFP receptors on the tumor cell surface and can be eﬃciently accumulated in tumor cells. In
addition, ApE1 was shown to be stable in storage and during its chemical modiﬁcation. An increased number of carboxyl groups
in the molecule allows the production of cytotoxic compound conjugates with higher drug-loading capacity and enhanced tumor
targeting potential.
1.Introduction
Activetargetingoftumorcellsviareceptor-mediatedendocy-
tosis has the potential to speciﬁcally enhance internalization
of drugs by target cells, while minimizing drug action
on healthy tissues. Oncofetal proteins (alpha-fetoprotein,
carcinoembryonic antigen) have been extensively used as
targetedvectorsforselectivedrugdelivery,sincetheyinteract
with speciﬁc surface receptors of tumor cells [1]. Human
alpha-fetoprotein (AFP) comprises three domains; the third
domain is responsible for binding to the cell surface of
manycancer types [2]. Our previous workyielded promising
results concerning the use of the recombinant third domain
of human alpha-fetoprotein (rhAFP3d) as a vector in archi-
tectures for targeted drug delivery [3–5]. Small rhAFP3d
peptide fragments are also currently being investigated∗∗.
A signiﬁcant shortcoming of rhAFP3d and peptide
fragments is that they cannot carry more than one or two
covalently attached drug molecules, because the number
of available reactive groups is small. To overcome this
limitation, two approaches were employed; one of them
involving drug-loaded rhAFP3d-conjugated nanoparticles
[5], and the other one using recombinant technologies to
obtain a new rhAFP3d-based protein vector with increased
number of reactive groups. The new vector protein was con-
structed based on the amino acid sequence of rhAFP3d with
receptor-binding activity fused to a C-terminal fragment of
22 glutamic acid residues (Figure 1). Thus, the chimeric
recombinant protein ApE1 was designed as a bifunctional
molecule, with one part responsible for speciﬁc targeting of
tumorcellsandtheotherpartplannedforbindingantitumor
agents.
In this work, our purpose was to create the genetic
construct and the producer strain for ApE1 expression, to
develop an eﬃcient method for ApE1 isolation from the
biomass, and to determine the ApE1 ability to selectively
interact with cancer cells.
2.MaterialsandMethods
2.1. Bacterial Strains and Plasmid. Host strains E. coli XL1-
Blue and E. coli SHuﬄe express T7 (NEB, USA) were
used for cloning and expression experiments. The plasmid2 Journal of Biomedicine and Biotechnology
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Figure 1: Amino acid composition of ApE1. Blue letters: rhAFP3d sequence, green: 22 glutamic acid residues, brown: Histag. N-, and
C-terminus of the protein are shown with red letters.
pET-28a(+) (Novagene, USA) was used as a cloning and
expression vector.
2.2.PlasmidConstruction. TotalRNAwasisolatedfromAFP-
producing human HepG2 hepatocellular carcinoma cells by
the Chomczynski procedure [6]. Human AFP cDNA was
obtainedbyreversetranscriptionusingRTAMVreversetran-
scriptase and the CTTCCCCTGAAGTAAT primer comple-
mentary to the 3 untranslated AFP mRNA region. The DNA
fragment encoding AFP amino acids 376–609 was ampliﬁed
with the primers TTTTCCATGGGATACCAGGAGTTATTG
(forward) and TTTTCTCGAGAACTCCCAAAGCAGCAC
(reverse). The PCR product was inserted into the pET28a(+)
expression vector at the NcoI/XhoI site by endonuclease
digestion and subsequent ligation. Following ampliﬁcation
in competent E. coli XL1-Blue cells, the pAFP28D3 plasmid
was isolated and identiﬁed by restriction endonuclease anal-
ysis.TheDNAsequencewasobtainedonanautomatedDNA
sequencer. Two rare tandem arginine codons AGG AGG
weresubstitutedwithCGT CGC toincreasethe recombinant
protein yield. The polyglutamate-encoding region was syn-
thesized by PCR using a pair of primers with complementary
C-end sequences: TTCTCGAGGAAGAAGAAGAAGAAG-
AAGAAGAGGAGGAGGAGGAG and TTTGTCGACTTC-
TTCTTCTTCTTCTTCTTCCTCCTCCTCCTCCTC, and
cloned into pAFP28D3 at the XhoI restriction site. The
resulting plasmid pAFP28D3PolyGlu was transferred in
competent E. coli XL1-Blue cells. Following ampliﬁcation,
plasmid DNA was isolated and identiﬁed by restriction
endonuclease analysis. The presence of the chimeric apE1
gene was conﬁrmed by DNA sequencing.
2.3. Selection of Producer Strain SHExT7 ApE1. Competent
E. coli Shuﬄe express T7 cells were transformed with the
pAFP28D3PolyGlu plasmid using the Inoue method
[7]. Resulting transformant colonies were selected
on a kanamycin-containing medium and tested for
ApE1 expression using 1.0mM/L of isopropyl β-D-1-
thiogalactopyranoside(IPTG)asaninductor.Theexpression
level was evaluated by SDS-PAGE using the ImageJ program.
2.4. Analysis of ApE1 Distribution between the Soluble and
Insoluble (Inclusion Bodies) Fractions. An aliquot of cell
suspension in phosphate buﬀered saline (PBS), pH 7.8, con-
taining0.3Msodiumchlorideandproteaseinhibitorphenyl-
methylsulfonyl ﬂuoride (PMSF) (Sigma-Aldrich, USA) was
treated with 2.5mg/L lysozyme for 15min at room tempera-
ture.Thencelllysatewasseveraltimessubjectedtoultrasonic
disintegration at 0◦C and centrifuged at 13000rpm for
10minutes at 4◦C. The supernatant and pellet were sepa-
rated and analyzed by gel electrophoresis using the ImageJ
program.
2.5. Isolation and Puriﬁcation of ApE1 from the Soluble
Fraction of SHExT7 ApE1 Producer. The soluble fraction of
producer strain biomass was tested for the presence of the
target protein by electrophoresis. The puriﬁcation procedure
included two stages. Primary puriﬁcation was performed
by ion exchange chromatography on DEAE-Sepharose CL-
6B (Sigma-Aldrich, USA). Brieﬂy, the supernatant of the
soluble fraction of producer strain biomass was loaded onto
the resin preequilibrated with PBS, pH 7.4. Next, the resin
was washed with 10 volumes of 0.2M sodium chloride in
PBS, pH 7.4, and the target protein was eluted with 0.4M
sodium chloride in PBS, pH 7.4. The protein-containing
eluate was dialyzed against PBS, pH 7.4, and additionally
puriﬁed by metal chelate chromatography on Chelating
Sepharose FFNi2+ (Amersham, UK). Brieﬂy, protein solution
was applied onto a Chelating Sepharose FFNi2+ column
equilibratedwithPBS,pH7.4,washedwith0.01Mimidazole
inPBS,pH7.4andthenelutedwith0.25MimidazoleinPBS,
pH 7.4. The eluate was dialyzed twice against PBS, pH 7.4, at
4◦C,ﬁrstfor4h,andnextforfurther15hoursafterchanging
the buﬀer.
2.6. Analysis of the Target Protein ApE1
2.6.1. SDS-PAGE. The level of ApE1 expression in the
producer strain and the target protein purity at all stages of
the puriﬁcation procedure were analyzed by Laemmli SDS-
PAGE [8].
2.6.2. Protein Concentration. Protein concentration was
determined by the standard procedure using a bicinchoninic
acid kit (BCA) (Sigma-Aldrich, USA) with bovine serum
albumin as a standard [9].
2.6.3. Detecting Free Sulfhydryl Groups. The presence of
free sulfhydryl (thiol) groups per protein molecule was
determined by the standard method using the Ellman’s
reagent [10].
2.6.4. Determining the Amino Acid Composition of ApE1.
For ApE1 identiﬁcation, its amino acid composition was
determined as described in [11]. An aliquot of the protein
was subjected to acid hydrolysis, and quantitative amino acidJournal of Biomedicine and Biotechnology 3
analysis was performed using an amino acid analyzer (L-
8800, Hitachi, Tokyo, Japan).
2.7.PreparationofFITC-LabeledApE1. FITC-labeledprotein
waspreparedaccordingtostandardprocedure.Brieﬂy,4-fold
molar excess of ﬂuorescein isothiocyanate (FITC) (Sigma-
Aldrich, USA) solution in dimethylsulfoxide was added to a
protein solution in PBS, pH 7.4, and incubated in the dark
f o r1 ha tr o o mt e m p e r a t u r e ,t h e nf o r1 8 ha t4 ◦C. FITC-
labeled protein was separated from free FITC on a Sephadex
G-25 column (Sigma-Aldrich, USA) equilibrated with PBS,
pH 7.4. Protein concentration was determined by BCA, and
the concentration of FITC was measured by absorbance at
498nm.
2.8. Cell Culture. Human breast adenocarcinoma MCF-7
cells were maintained in DMEM medium (Sigma-Aldrich,
USA) containing 10% fetal bovine serum (FBS, Gibco, USA)
and 50mg/mL of gentamicin in a CO2 incubator at 37◦C
in a humidiﬁed atmosphere containing 5% CO2. Peripheral
blood lymphocytes of healthy volunteers were isolated by
density gradient centrifugation on a Ficoll-Paque gradient
(Sigma-Aldrich, USA).
2.9. Binding and Uptake of FITC-Labeled ApE1. The binding
and uptake of FITC-labeled ApE1 were studied using the
technique described previously [3]. Before the experiment,
cells were incubated for 2h in FBS-free DMEM medium.
FITC-labeled ApE1 (0.25–4μM) was added to the cell
suspension in PBS and cells were incubated for 1h at 4◦C
(for the binding assay) or 37◦C (for the uptake assay). After
incubation, cells were washed twice with PBS and ﬁxed with
2% paraformaldehyde. Fluorescence was measured using an
EPICS XL ﬂow cytometer (Beckman Coulter, USA) and
analyzed using the XL SYSTEM II software. The mean
ﬂuorescence intensity (MFI) was determined in each sample
(105 cells). The speciﬁcity of ApE1-FITC binding to the AFP
receptor was determined by preliminary incubation of cells
in the presence of a 30-fold excess of free ApE1 or rhAFP3d.
3. Results andDiscussion
Weobtained aplasmidconstructencoding aproteinwiththe
desired amino acid sequence (Figure 1). A His-Tag-encoding
sequence was also included in the construct to facilitate
puriﬁcation. An earlier study [12] showed that rhAFP3d was
expressedintheinsolubleform(asinclusionbodies)andhad
to be renaturated. However, renaturation was strongly com-
plicated by the fact that the rhAFP3d contains six disulﬁde
bonds and shows inherently hydrophobic properties. Under
these considerations, E. coli SHuﬄe express T7 was chosen
as the host strain for transformation. SHuﬄei sam u t a n tE.
colistrain lacking two reductases(trxB and gor) and carrying
an additional suppressor mutation (ahpC). SHuﬄee x p r e s s
T7 cells also contain cytoplasmic disulﬁde bond isomerase
DsbC, which allows producing recombinant proteins with
disulﬁde bonds in the cytoplasm.
Figure 2: 15% SDS-PAGE of the total biomass before induction
(left) and after induction (right). The arrow indicates the target
protein ApE1 with predicted mass of 30kDa.
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Figure 3: 15% SDS-PAGE of the puriﬁed target protein. The arrow
indicates the target protein ApE1 with predicted mass of 30kDa.
Molecular weight markers are shown at the left.
The observed expression level of the target protein with
a predicted molecular mass of 30 kDa was 30–40 mg/mL,
or 25% of total cellular proteins (Figure 2). An analysis of
the ApE1 distribution between the soluble- and insoluble-
(inclusion bodies) protein fractions showed that more than
80% of ApE1 was synthesized in the soluble form. For
this reason, we further concentrated on developing the
procedure of protein isolation and puriﬁcation from the
soluble fraction of biomass.
Since the novel ApE1 protein is more hydrophilic than
rhAFP3d and is synthesized in the soluble form, the isolation
and puriﬁcation procedure is not complicated by refolding.
After trying out several methods, we chose the two-step
puriﬁcation procedure described above as the simplest and
the most eﬃcient one. The target protein yield at successive
puriﬁcation stages is shown in Table 1.
Target protein puriﬁed by this method (Figure 3) in the
concentrationof1.5–2.0mg/mLhad95%purityandshowed4 Journal of Biomedicine and Biotechnology
Table 1: Yield of the target protein ApE1 in successive puriﬁcation stages.
Stages ApE1∗ output (from 1 L of culture medium), mg Yield, %
Biomass 40 100
Soluble fraction 32 80
1st puriﬁcation step (DEAE-Sepharose CL6B) 30 75
2nd puriﬁcation step (Chelating Sepharose FF) 28 70
Puriﬁed ApE1 28 70
∗The target protein amounts were determined using the ImageJ program after SDSPAGE.
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Figure 4: Elution proﬁle of ApE1 hydrolysate. Arrow indicates the
retention time of the glutamic acid.
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Figure 5: Binding and uptake of FITC-labeled ApE1 into human
breast adenocarcinoma MCF-7 cells and peripheral blood lympho-
cytes.
lack of thiol groups in the molecule. The latter fact allows us
to speculate that ApE1 refolding occurs during the growth of
cell cultures.
An analysis of amino acid composition was performed
to conﬁrm the presence of 22 glutamic acid residues, and
showed that the amino acid content of target protein
(Figure 4) corresponded to the predicted.
To determine whether the modiﬁed protein retained the
ability to bind to cancer cells and to be accumulated in them,
an FITC-labeled derivative of ApE1 was synthesized. The
protein/ﬂuorescein molar ratio was deﬁned as the ratio of
molesofproteintomolesofFITCintheconjugate.Toobtain
this ratio, ApE1 concentration was determined by BCA,
and FITC concentration was determined by measuring the
conjugate absorbance at 495nm. The protein/FITC molar
ratio in FITC-labeled ApE1 was 1/1. The binding and uptake
of FITC-labeled ApE1 were studied in MCF-7 human breast
adenocarcinomacells,whicharecharacterizedbyahighlevel
of AFP receptor expression (300000 receptors per cell) [2].
Flow cytometry analysis conﬁrmed the ability of ApE1 to
bind to MCF-7 cells (Figure 5). Incubation of MCF-7 cells
with FITC-labeled ApE1 at 37◦Cr e s u l t e di nh i g hl e v e l so f
accumulation of FITC-labeled ApE1 in the cells, indicating
the possible role of receptor-mediated endocytosis in the
uptake of ApE1 by tumor cells. Unstimulated peripheral
blood lymphocytes were characterized with signiﬁcantly
lower binding and uptake of FITC-labeled ApE1 than MCF-
7 cells, which conﬁrmed the speciﬁcity of ApE1 binding to
tumor cells.
It was shown previously that the speciﬁcity of rhAFP3d
binding to AFP receptors on MCF-7 cells was the same as
that of AFP [3]. In this work, we analyzed the ability of
FITC-labeled ApE1 to speciﬁcally bind to AFP receptors in
the presence of excessive amounts of ApE1 or rAFP3d. The
level of ApE1-FITC binding to MCF-7 cells was signiﬁcantly
decreased in the presence of a 30-fold excess of free ApE1 or
rhAFP3d, which conﬁrmed the speciﬁcity of ApE1 binding
to the AFP receptor on the surface of tumor cells (Figure 6).
Both ApE1 and rhAFP3d blocked the ApE1-FITC binding
equally. Apparently, ApE1 competes with rhAFP3d for the
binding site of the AFP receptor, and the receptor-binding
activity of ApE1 is similar to that of rhAFP3d.
4. Conclusion
Previous studies have shown the eﬃciency of rhAFP3d as a
vectorinthemacromoleculearchitecturesthatcanselectively
target cancer cells [4, 5]. Based on the rhAFP3d sequence,
we obtained a chimeric protein named ApE1, with a higher
content of carboxyl groups that can be used for covalent
attachment of anticancer drugs. In this work, we developed
the procedure for ApE1 isolation and puriﬁcation from
producer biomass. The speciﬁcity of ApE1 binding to the
AFP receptor and the high level of accumulation of ApE1
in tumor cells suggest that ApE1 can be eﬃciently used as
a vector molecule for targeted delivery of anti-cancer drugs.Journal of Biomedicine and Biotechnology 5
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Figure 6: Inhibition of FITC-labeled ApE1 binding to MCF-7 cells
in the presence of excess of free ApE1 or rhAFP3d.
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